Abstract
ABC transporters protect the brain by transporting neurotoxic compounds from the brain back into the blood. P-glycoprotein (P-gp) is the most investigated ABC (efflux) transporter, as it is implicated in neurodegenerative diseases such as Alzheimer's disease. Altered function of P-gp can be studied in vivo, using Positron Emission Tomography (PET). To date, several radiopharmaceuticals have been developed to image P-gp function in vivo. So far, attempts to image expression levels of P-gp using radiolabeled P-gp inhibitors have not been successful. Improved knowledge of compound behavior toward P-gp from in vitro studies should increase predictability of in vivo outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 362-371 |
| Number of pages | 10 |
| Journal | Clinical Pharmacology & Therapeutics |
| Volume | 97 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr-2015 |
Keywords
- POSITRON-EMISSION-TOMOGRAPHY
- CANCER RESISTANCE PROTEIN
- P-GLYCOPROTEIN FUNCTION
- DRUG EFFLUX TRANSPORTERS
- IN-VIVO EVALUATION
- MULTIDRUG-RESISTANCE
- PARKINSONS-DISEASE
- TARIQUIDAR XR9576
- PET
- INHIBITOR